文献速递血栓与止血

利妥昔单抗联合免疫耐受诱导根除重型A型血友病高滴度抑制物的结局:指数衰减模型与不同结局的RNA测序基因表达谱

Outcomes of immune tolerance induction with rituximab to eradicate high-titer inhibitor of hemophilia A: depicted by exponential decay model and the gene expression profile of different outcomes by RNA-sequencing.
PubMed 文献 · J Thromb Haemost · 2025-04-24

研究前瞻性纳入76例使用低剂量免疫耐受诱导(ITI)联合1–3轮利妥昔单抗的高滴度抑制物A型血友病患儿,评估抑制物转阴结局及速度。首轮后53.9%(41/76)转阴,第二轮后65.8%(50/76),第三轮后67.1%(51/76);抑制物衰减符合指数衰减曲线。RNA测序比较4例失败与4例快速转阴患者的基因表达谱。

要点

  • 低剂量ITI联合利妥昔单抗后,67.1%(51/76)患儿抑制物转阴。
  • 抑制物衰减符合指数衰减曲线,模型可估算达到特定滴度的时间。
  • 首轮利妥昔单抗后复发和不良结局事件早发为新观察到的预后不良因素。

核心结论

  • 接受ITI联合利妥昔单抗治疗的高滴度抑制物A型血友病患儿中67.1%(51/76)实现抑制物转阴。
  • 基于抑制物滴度衰减曲线的模型可用于预测结局。
  • 体液免疫反应及补体和凝血级联可能作为影响ITI结局的信号。

研究设计与样本

  • 前瞻性研究,纳入76例高滴度抑制物A型血友病患儿,使用低剂量ITI联合1–3轮利妥昔单抗。
  • 评估结局为成功或失败及抑制物转阴(IN)速度(快速或缓慢)。
  • 全转录组RNA测序分析4例失败患者(排除F8大缺失)和4例快速成功转阴患者的基因表达谱。
  • 临床试验注册号:NCT03598725。

主要发现

  • 首轮利妥昔单抗后成功转阴41/76(53.9%),第二轮后50/76(65.8%),第三轮后51/76(67.1%)。
  • 抑制物衰减曲线符合指数衰减曲线,模型t=ln(Y0-PlateauY-Plateau)k可估算ITI-利妥昔单抗期间达到特定抑制物滴度的时间。
  • 新观察到的预后不良因素包括首轮利妥昔单抗后复发和不良结局事件早发。
  • 与快速成功转阴患者相比,失败患者有186个上调差异表达基因(DEGs)和176个下调DEGs。
  • 上调DEGs包括CXCL8、NLRP6、CHI3L1、CLEC9A、THBD和PROS1;下调DEGs包括STAT1、TLR7、C1Q、C2、IDO1和CD38。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Eradication of inhibitors is still a desirable goal for patients with hemophilia A inhibitors. Combining rituximab with immune tolerance induction (ITI) is the secondline regimen, but data and predictors are limited. OBJECTIVES: To evaluate the efficacy of ITI-rituximab and to identify the predictors of prognosis. METHODS: In total, 76 children with high-titer inhibitor prospectively using low-dose ITI together with 1-3 round(s) of rituximab were evaluated for outcomes: success or failure and rapidity (rapid or slow) of inhibitor negativity (ie, inhibitor titers turned negative, inhibitor negativity [IN]). The whole-transcriptome RNA-sequencing (RNA-seq) was used to analyze the gene expression profile of 4 failure patients (excluding F8 large deletion) and 4 rapid success-IN patients. RESULTS: Success IN was achieved in 41 of 76 (53.9%) patients after first-round of rituximab, 50 of 76 (65.8%) after second-round of rituximab, and 51 of 76 (67.1%) after third-round of rituximab. Profile of inhibitor decay followed an exponential decay curve. Time to a given inhibitor titer during ITI-rituximab could be estimated by the model t=ln(Y0-PlateauY-Plateau)k. The newly observed poor prognostic factors included relapse after the first-round of rituximab and early occurence of poor-outcome events. RNA-seq analysis showed 186 upregulated differential expressed genes (DEGs) and 176 downregulated DEGs in failure subjects compared with those in patients with rapid success IN. The upregulated DEGs included CXCL8, NLRP6, CHI3L1, CLEC9A, THBD, and PROS1. The downregulated DEGs included STAT1, TLR7, C1Q, C2, IDO1, and CD38. CONCLUSION: Success IN was achieved in 67% of children with hemophilia A with high-titer inhibitor treated by ITI-rituximab. A model based on the profile of inhibitor-titer decay can be used for predicting outcomes. Humoral immune response and complement and coagulation cascades may act as signals that influence ITI outcomes (ClinicalTrials.gov: NCT03598725).

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Li Z, Tang Y, Chen Z, et al. Outcomes of immune tolerance induction with rituximab to eradicate high-titer inhibitor of hemophilia A: depicted by exponential decay model and the gene expression profile of different outcomes by RNA-sequencing. J Thromb Haemost. 2025. PMID: 40286913. doi:10.1016/j.jtha.2025.04.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。